Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer
What is known and Objective Compared with other molecular subtypes, hormone receptor‐positive breast cancer often shows worse neoadjuvant chemotherapy efficacy. This study aims to explore the relationship between the oestrogen receptor (ER)‐related genes carbonic anhydrase 12 (CA12) and trefoil fact...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2022-05, Vol.47 (5), p.609-618 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 618 |
|---|---|
| container_issue | 5 |
| container_start_page | 609 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 47 |
| creator | Shen, Mengjia Yang, Libo Lei, Ting Zhang, Peichuan Xiao, Lin Cao, Shiyu Chen, Fei Li, Li Ye, Feng Bu, Hong |
| description | What is known and Objective
Compared with other molecular subtypes, hormone receptor‐positive breast cancer often shows worse neoadjuvant chemotherapy efficacy. This study aims to explore the relationship between the oestrogen receptor (ER)‐related genes carbonic anhydrase 12 (CA12) and trefoil factor 3 (TFF3) and their predictive value of neoadjuvant chemotherapy for breast cancer.
Methods
We investigated the relationships between CA12, TFF3 and ER status and their predictive value of anthracycline‐taxane neoadjuvant chemotherapy in 115 female breast cancer patients via real‐time polymerase chain reaction (RT‐PCR) and 4 GEO datasets: GSE41998, GSE25065, GSE20194 and GSE20271. Then, the effects of CA12 and TFF3 on the chemotherapy drugs doxorubicin and docetaxel were verified in vitro in the breast cancer cell lines MCF‐7 and BT474.
Results and Discussion
The GEO datasets and RT‐PCR results showed that the relative expression of both CA12 and TFF3 was higher in oestrogen receptor‐positive samples compared with the other samples (p |
| doi_str_mv | 10.1111/jcpt.13580 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2634848034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2666408514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3930-24419956e9d36d95ef9171693f74c8e92073161ea27f20902fb242655c7059903</originalsourceid><addsrcrecordid>eNp90ctKxDAUBuAgio6XjQ8gATciVHNPs5TieEHQxbgumfQUO3SamrTKvL2ZGXXhwmwSyMfP4fwInVJyRdO5Xrh-uKJc5mQHTShXMmOakl00IUyZTGimD9BhjAtCiNKM76MDLhkznMsJCoUPAVo7NL7Dcxg-ATpc3FCGbVfh2XTKN4_hDZqA-wBV4zb0w7YjYF_jDrytFuOH7Qbs3mDpEw22X-EAsfddBNyk4AA2pn_bOQjHaK-2bYST7_sIvU5vZ8V99vR891DcPGWOG04yJgQ1RiowFVeVkVAbqqkyvNbC5WAY0ZwqCpbpmhFDWD1ngikpnSbSGMKP0MU2tw_-fYQ4lMsmOmhbm2YeY8kUF7nICReJnv-hCz-GLk2XlFKC5JKu1eVWueBjDFCXfWiWNqxKSsp1E-W6iXLTRMJn35HjfAnVL_1ZfQJ0Cz6bFlb_RJWPxctsG_oFI_aRWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2666408514</pqid></control><display><type>article</type><title>Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Shen, Mengjia ; Yang, Libo ; Lei, Ting ; Zhang, Peichuan ; Xiao, Lin ; Cao, Shiyu ; Chen, Fei ; Li, Li ; Ye, Feng ; Bu, Hong</creator><creatorcontrib>Shen, Mengjia ; Yang, Libo ; Lei, Ting ; Zhang, Peichuan ; Xiao, Lin ; Cao, Shiyu ; Chen, Fei ; Li, Li ; Ye, Feng ; Bu, Hong</creatorcontrib><description><![CDATA[What is known and Objective
Compared with other molecular subtypes, hormone receptor‐positive breast cancer often shows worse neoadjuvant chemotherapy efficacy. This study aims to explore the relationship between the oestrogen receptor (ER)‐related genes carbonic anhydrase 12 (CA12) and trefoil factor 3 (TFF3) and their predictive value of neoadjuvant chemotherapy for breast cancer.
Methods
We investigated the relationships between CA12, TFF3 and ER status and their predictive value of anthracycline‐taxane neoadjuvant chemotherapy in 115 female breast cancer patients via real‐time polymerase chain reaction (RT‐PCR) and 4 GEO datasets: GSE41998, GSE25065, GSE20194 and GSE20271. Then, the effects of CA12 and TFF3 on the chemotherapy drugs doxorubicin and docetaxel were verified in vitro in the breast cancer cell lines MCF‐7 and BT474.
Results and Discussion
The GEO datasets and RT‐PCR results showed that the relative expression of both CA12 and TFF3 was higher in oestrogen receptor‐positive samples compared with the other samples (p < 0.05). CA12 was significantly correlated with TFF3 (p < 0.05). In MCF‐7 cells, inhibition of TFF3 induced downregulation of CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 also downregulated TFF3 and ESR1 (p < 0.05). In BT474 cells, inhibition of TFF3 downregulated CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 led to slight upregulation of TFF3 and ESR1 (p > 0.05). Moreover, GEO datasets and RT‐PCR results showed that CA12 and TFF3 were more highly expressed in nonpathological complete response (non‐pCR) samples than in pCR samples (p < 0.05). Cell viability assays of MCF‐7 and BT474 cells showed that inhibiting CA12 and TFF3 could enhance sensitivity to doxorubicin and docetaxel (p < 0.05).
What is new and Conclusion
CA12 and TFF3 were correlated with each other, and their high expression might explain the worse efficacy of neoadjuvant chemotherapy in oestrogen receptor‐positive breast cancer patients.]]></description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.13580</identifier><identifier>PMID: 35229335</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Anthracycline ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; CA12 ; Carbonic Anhydrases ; Cell viability ; Chemotherapy ; Datasets ; Docetaxel - pharmacology ; Doxorubicin ; Doxorubicin - therapeutic use ; ESR1 protein ; Female ; Humans ; Kinases ; mRNA ; Neoadjuvant Therapy ; Polymerase chain reaction ; Receptors, Estrogen - metabolism ; Receptors, Estrogen - therapeutic use ; RNA, Messenger ; taxanes ; TFF3 ; Trefoil factor ; Trefoil Factor-3 - genetics ; Tumor cell lines</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2022-05, Vol.47 (5), p.609-618</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><rights>Copyright © 2022 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3930-24419956e9d36d95ef9171693f74c8e92073161ea27f20902fb242655c7059903</citedby><cites>FETCH-LOGICAL-c3930-24419956e9d36d95ef9171693f74c8e92073161ea27f20902fb242655c7059903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.13580$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.13580$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35229335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Mengjia</creatorcontrib><creatorcontrib>Yang, Libo</creatorcontrib><creatorcontrib>Lei, Ting</creatorcontrib><creatorcontrib>Zhang, Peichuan</creatorcontrib><creatorcontrib>Xiao, Lin</creatorcontrib><creatorcontrib>Cao, Shiyu</creatorcontrib><creatorcontrib>Chen, Fei</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Ye, Feng</creatorcontrib><creatorcontrib>Bu, Hong</creatorcontrib><title>Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description><![CDATA[What is known and Objective
Compared with other molecular subtypes, hormone receptor‐positive breast cancer often shows worse neoadjuvant chemotherapy efficacy. This study aims to explore the relationship between the oestrogen receptor (ER)‐related genes carbonic anhydrase 12 (CA12) and trefoil factor 3 (TFF3) and their predictive value of neoadjuvant chemotherapy for breast cancer.
Methods
We investigated the relationships between CA12, TFF3 and ER status and their predictive value of anthracycline‐taxane neoadjuvant chemotherapy in 115 female breast cancer patients via real‐time polymerase chain reaction (RT‐PCR) and 4 GEO datasets: GSE41998, GSE25065, GSE20194 and GSE20271. Then, the effects of CA12 and TFF3 on the chemotherapy drugs doxorubicin and docetaxel were verified in vitro in the breast cancer cell lines MCF‐7 and BT474.
Results and Discussion
The GEO datasets and RT‐PCR results showed that the relative expression of both CA12 and TFF3 was higher in oestrogen receptor‐positive samples compared with the other samples (p < 0.05). CA12 was significantly correlated with TFF3 (p < 0.05). In MCF‐7 cells, inhibition of TFF3 induced downregulation of CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 also downregulated TFF3 and ESR1 (p < 0.05). In BT474 cells, inhibition of TFF3 downregulated CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 led to slight upregulation of TFF3 and ESR1 (p > 0.05). Moreover, GEO datasets and RT‐PCR results showed that CA12 and TFF3 were more highly expressed in nonpathological complete response (non‐pCR) samples than in pCR samples (p < 0.05). Cell viability assays of MCF‐7 and BT474 cells showed that inhibiting CA12 and TFF3 could enhance sensitivity to doxorubicin and docetaxel (p < 0.05).
What is new and Conclusion
CA12 and TFF3 were correlated with each other, and their high expression might explain the worse efficacy of neoadjuvant chemotherapy in oestrogen receptor‐positive breast cancer patients.]]></description><subject>Anthracycline</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>CA12</subject><subject>Carbonic Anhydrases</subject><subject>Cell viability</subject><subject>Chemotherapy</subject><subject>Datasets</subject><subject>Docetaxel - pharmacology</subject><subject>Doxorubicin</subject><subject>Doxorubicin - therapeutic use</subject><subject>ESR1 protein</subject><subject>Female</subject><subject>Humans</subject><subject>Kinases</subject><subject>mRNA</subject><subject>Neoadjuvant Therapy</subject><subject>Polymerase chain reaction</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Estrogen - therapeutic use</subject><subject>RNA, Messenger</subject><subject>taxanes</subject><subject>TFF3</subject><subject>Trefoil factor</subject><subject>Trefoil Factor-3 - genetics</subject><subject>Tumor cell lines</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90ctKxDAUBuAgio6XjQ8gATciVHNPs5TieEHQxbgumfQUO3SamrTKvL2ZGXXhwmwSyMfP4fwInVJyRdO5Xrh-uKJc5mQHTShXMmOakl00IUyZTGimD9BhjAtCiNKM76MDLhkznMsJCoUPAVo7NL7Dcxg-ATpc3FCGbVfh2XTKN4_hDZqA-wBV4zb0w7YjYF_jDrytFuOH7Qbs3mDpEw22X-EAsfddBNyk4AA2pn_bOQjHaK-2bYST7_sIvU5vZ8V99vR891DcPGWOG04yJgQ1RiowFVeVkVAbqqkyvNbC5WAY0ZwqCpbpmhFDWD1ngikpnSbSGMKP0MU2tw_-fYQ4lMsmOmhbm2YeY8kUF7nICReJnv-hCz-GLk2XlFKC5JKu1eVWueBjDFCXfWiWNqxKSsp1E-W6iXLTRMJn35HjfAnVL_1ZfQJ0Cz6bFlb_RJWPxctsG_oFI_aRWg</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Shen, Mengjia</creator><creator>Yang, Libo</creator><creator>Lei, Ting</creator><creator>Zhang, Peichuan</creator><creator>Xiao, Lin</creator><creator>Cao, Shiyu</creator><creator>Chen, Fei</creator><creator>Li, Li</creator><creator>Ye, Feng</creator><creator>Bu, Hong</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>202205</creationdate><title>Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer</title><author>Shen, Mengjia ; Yang, Libo ; Lei, Ting ; Zhang, Peichuan ; Xiao, Lin ; Cao, Shiyu ; Chen, Fei ; Li, Li ; Ye, Feng ; Bu, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3930-24419956e9d36d95ef9171693f74c8e92073161ea27f20902fb242655c7059903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anthracycline</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>CA12</topic><topic>Carbonic Anhydrases</topic><topic>Cell viability</topic><topic>Chemotherapy</topic><topic>Datasets</topic><topic>Docetaxel - pharmacology</topic><topic>Doxorubicin</topic><topic>Doxorubicin - therapeutic use</topic><topic>ESR1 protein</topic><topic>Female</topic><topic>Humans</topic><topic>Kinases</topic><topic>mRNA</topic><topic>Neoadjuvant Therapy</topic><topic>Polymerase chain reaction</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Estrogen - therapeutic use</topic><topic>RNA, Messenger</topic><topic>taxanes</topic><topic>TFF3</topic><topic>Trefoil factor</topic><topic>Trefoil Factor-3 - genetics</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shen, Mengjia</creatorcontrib><creatorcontrib>Yang, Libo</creatorcontrib><creatorcontrib>Lei, Ting</creatorcontrib><creatorcontrib>Zhang, Peichuan</creatorcontrib><creatorcontrib>Xiao, Lin</creatorcontrib><creatorcontrib>Cao, Shiyu</creatorcontrib><creatorcontrib>Chen, Fei</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Ye, Feng</creatorcontrib><creatorcontrib>Bu, Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Mengjia</au><au>Yang, Libo</au><au>Lei, Ting</au><au>Zhang, Peichuan</au><au>Xiao, Lin</au><au>Cao, Shiyu</au><au>Chen, Fei</au><au>Li, Li</au><au>Ye, Feng</au><au>Bu, Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2022-05</date><risdate>2022</risdate><volume>47</volume><issue>5</issue><spage>609</spage><epage>618</epage><pages>609-618</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract><![CDATA[What is known and Objective
Compared with other molecular subtypes, hormone receptor‐positive breast cancer often shows worse neoadjuvant chemotherapy efficacy. This study aims to explore the relationship between the oestrogen receptor (ER)‐related genes carbonic anhydrase 12 (CA12) and trefoil factor 3 (TFF3) and their predictive value of neoadjuvant chemotherapy for breast cancer.
Methods
We investigated the relationships between CA12, TFF3 and ER status and their predictive value of anthracycline‐taxane neoadjuvant chemotherapy in 115 female breast cancer patients via real‐time polymerase chain reaction (RT‐PCR) and 4 GEO datasets: GSE41998, GSE25065, GSE20194 and GSE20271. Then, the effects of CA12 and TFF3 on the chemotherapy drugs doxorubicin and docetaxel were verified in vitro in the breast cancer cell lines MCF‐7 and BT474.
Results and Discussion
The GEO datasets and RT‐PCR results showed that the relative expression of both CA12 and TFF3 was higher in oestrogen receptor‐positive samples compared with the other samples (p < 0.05). CA12 was significantly correlated with TFF3 (p < 0.05). In MCF‐7 cells, inhibition of TFF3 induced downregulation of CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 also downregulated TFF3 and ESR1 (p < 0.05). In BT474 cells, inhibition of TFF3 downregulated CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 led to slight upregulation of TFF3 and ESR1 (p > 0.05). Moreover, GEO datasets and RT‐PCR results showed that CA12 and TFF3 were more highly expressed in nonpathological complete response (non‐pCR) samples than in pCR samples (p < 0.05). Cell viability assays of MCF‐7 and BT474 cells showed that inhibiting CA12 and TFF3 could enhance sensitivity to doxorubicin and docetaxel (p < 0.05).
What is new and Conclusion
CA12 and TFF3 were correlated with each other, and their high expression might explain the worse efficacy of neoadjuvant chemotherapy in oestrogen receptor‐positive breast cancer patients.]]></abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>35229335</pmid><doi>10.1111/jcpt.13580</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2022-05, Vol.47 (5), p.609-618 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2634848034 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anthracycline Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology CA12 Carbonic Anhydrases Cell viability Chemotherapy Datasets Docetaxel - pharmacology Doxorubicin Doxorubicin - therapeutic use ESR1 protein Female Humans Kinases mRNA Neoadjuvant Therapy Polymerase chain reaction Receptors, Estrogen - metabolism Receptors, Estrogen - therapeutic use RNA, Messenger taxanes TFF3 Trefoil factor Trefoil Factor-3 - genetics Tumor cell lines |
| title | Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A18%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20CA12%20and%20TFF3%20and%20their%20prediction%20value%20of%20neoadjuvant%20chemotherapy%20response%20in%20breast%20cancer&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Shen,%20Mengjia&rft.date=2022-05&rft.volume=47&rft.issue=5&rft.spage=609&rft.epage=618&rft.pages=609-618&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1111/jcpt.13580&rft_dat=%3Cproquest_cross%3E2666408514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2666408514&rft_id=info:pmid/35229335&rfr_iscdi=true |